Cardiac paraganglioma is a rare neuroendocrine neoplasm arising from paraganglia associated with the heart and great vessels. It may develop in the atrial region, atrioventricular grooves, near the coronary arteries or at the root of the great vessels, sometimes extending extensively and complexly within the pericardium. Its location reflects the distribution of paraganglionic tissue and the cardiac autonomic plexus. Two features govern management: abundant vascularization and possible catecholamine production, which can add systemic injury to the local effects of the mass.
Current classification attributes metastatic potential to paragangliomas and distinguishes localized from metastatic disease. A relatively orderly histological appearance does not guarantee definitively benign behavior; detection of metastases at sites that do not normally contain paraganglionic tissue establishes dissemination. Assessment must therefore consider hormonal activity, extent, genetics and progression over time, even when the lesion appears well circumscribed and is completely excised.
Cardiac forms constitute a small proportion of primary heart tumors and extra-adrenal paragangliomas. They have been reported at various ages, with many diagnoses in adults, but published series are too selected to provide a precise population incidence. The frequent involvement of predisposition genes makes genetic counseling particularly important: the mass may be the first manifestation of an inherited condition and may coexist with other paraganglionic lesions.
Paraganglia are clusters of neuroendocrine cells distributed along the autonomic nervous system. Their persistence in the chest and heart explains the origin of tumors in regions seemingly distant from the adrenal gland. The term paraganglioma denotes this extra-adrenal origin, whereas pheochromocytoma refers to a neoplasm of the adrenal medulla; the two entities are often grouped under the acronym PPGL. Cardiac lesions may have very close relationships with the vascular adventitia and coronary arteries, making it difficult to distinguish anatomically between the site of origin and local secondary extension.
Among molecular predispositions, variants in SDHx genes are especially important in cardiac series. These genes encode components or associated factors of succinate dehydrogenase, a complex involved in both the tricarboxylic acid cycle and the mitochondrial respiratory chain. Loss of function disrupts succinate metabolism and promotes pseudohypoxia signaling, meaning activation of hypoxia-like cellular responses despite the presence of oxygen. This leads to alterations in epigenetic regulation, proliferation and angiogenesis, consistent with the mass's extensive vascular network.
SDHB, SDHC and SDHD are frequently represented in published series, but genetic panels are defined according to context and may include other PPGL-predisposition genes. SDHB variants are associated, at the group level, with greater metastatic risk; SDHD variants may accompany multifocal disease and require attention to parental-origin effects on inheritance and expression. These associations guide surveillance and counseling without determining an individual patient's outcome with certainty.
A negative family history is compatible with inherited predisposition because of incomplete penetrance, delayed recognition or other genetic mechanisms. Molecular findings must therefore be interpreted alongside the phenotype, distinguishing a pathogenic variant from a variant of uncertain significance. Genetics can alter the search for other tumors and the evaluation of relatives, in addition to immediate cardiac management.
The secretory profile is often noradrenergic, with production of norepinephrine and its metabolite normetanephrine. Some patients also have a dopaminergic component, assessable with 3-methoxytyramine when available and indicated; other masses are biochemically silent. The amount of hormone produced, continuous or intermittent release and tissue sensitivity influence the clinical presentation. Size and symptom severity do not necessarily correlate: a small lesion can be functional, while a large mass may be detected mainly because of compression.
The lesion is generally highly vascular and may contain areas of hemorrhage or degeneration. Histologically, neuroendocrine cells arranged in nests, traditionally termed Zellballen, are separated by a delicate vascular network and accompanied by sustentacular cells. Positivity for markers such as chromogranin and synaptophysin supports neuroendocrine differentiation; sustentacular-cell markers and other investigations are interpreted in their morphological context. The abundant capillaries explain the intense enhancement on imaging and the risk of bleeding during manipulation of the mass.
Immunohistochemistry for SDHB, and for SDHA when relevant, may suggest a defect of the succinate dehydrogenase complex and guide further genetic investigation. Loss of expression alone does not identify which gene is altered and does not replace molecular testing. Conversely, retained staining does not settle every possible inherited issue. The pathology report must also describe proliferation, necrosis, invasion and margins, providing information for an overall risk assessment.
Proliferative indices and grading systems, including GAPP, can contribute to stratification, but have limitations and do not certify the absence of future dissemination. Local extension into adjacent structures is relevant to resectability, whereas metastatic disease requires identification of lesions at sites such as lymph nodes, bone, liver or lung, assessed in context. In carriers of genetic predisposition, a second mass at another paraganglionic site may be a separate primary tumor: multifocality must be distinguished from metastasis because it entails different management pathways.
Catecholamine excess produces vasoconstriction, increased afterload and cardiac stimulation. Blood pressure may be persistently elevated or fluctuate markedly during secretory episodes. Chronic contraction of effective circulating volume contributes to possible orthostatic hypotension, even in someone who experiences hypertensive episodes. The blood-pressure response is therefore dynamic and can change with posture, medications, anesthesia and tumor manipulation.
Myocardial injury involves imbalance between oxygen supply and demand, microvascular alterations, intracellular calcium overload and metabolic stress. Catecholamine-induced cardiomyopathy, dilated dysfunction or Takotsubo-like syndromes may develop, progressing to pulmonary edema and shock. Some dysfunction may improve after secretion is controlled and the neoplasm treated, whereas prolonged structural injury may limit recovery. Severity does not depend solely on anatomical obstruction by the mass.
Arrhythmias may result from adrenergic stimulation, ischemia and local involvement of cardiac tissues. Sinus tachycardia and supraventricular or ventricular arrhythmias must be interpreted in the hormonal context. The mass can also compress a coronary artery, deform an atrium or interfere with a valve, causing symptoms even without proven hypersecretion. The endocrine and mechanical mechanisms may coexist and require complementary interventions.
A catecholamine crisis may occur spontaneously or be triggered by stimuli, medications or procedures. A blood-pressure surge can accompany ischemia, arrhythmia, neurological injury or multiorgan failure; other presentations feature hypotension and collapse due to severe cardiac dysfunction. This variability explains the importance of recognizing a possible diagnosis before biopsy, anesthesia or resection. Normal blood pressure during an office visit does not mean that a tumor is nonfunctional.
The combination of headache, palpitations and sweating suggests catecholamine excess, especially when episodic and accompanied by pallor or marked blood-pressure fluctuations. Patients may report tremor, sudden anxiety, nausea, heat intolerance or weight loss. These symptoms are nonspecific but acquire significance when associated with a cardiac mass or known predisposition. The classic triad may be incomplete, and diagnosis should not depend on all its elements being present.
Predominantly cardiac presentations include chest pain, dyspnea, syncope, arrhythmias and heart failure. A silent paraganglioma may be discovered on CT or MRI because of its hypervascular appearance. In patients with unexplained cardiomyopathy, hypertensive episodes or an unusual hemodynamic response to a procedure, the endocrine hypothesis may precede identification of the cardiac site. Investigation of the cause must connect systemic symptoms with tumor anatomy.
The medication history evaluates drugs and substances that may provoke adrenergic symptoms, interfere with assays or precipitate a crisis. Relevant exposures include certain antidepressants, sympathomimetics, stimulants and prior reactions during anesthesia or manipulation. Family history assesses PPGL and manifestations of predisposing syndromes, including renal or gastrointestinal neoplasms when relevant to the genetic context. Documentation of any previously removed tumors should be reviewed because it may alter interpretation of the new mass.
During the physical examination, blood pressure and heart rate are measured under suitable conditions, including assessment of the standing response when the patient is stable. Signs of congestion, hypoperfusion, murmurs, arrhythmias and abnormalities associated with hereditary syndromes are sought. Ambulatory blood-pressure monitoring can document variability but does not replace biochemical investigations. In acute presentations, priority is to identify organ injury and stabilize the patient in a setting equipped to manage rapid, major hemodynamic changes.
Initial assessment of secretory activity relies on plasma free metanephrines or 24-hour fractionated urinary metanephrines, according to availability and suitability. Intratumoral production of metabolites makes these tests more useful than isolated episodic catecholamine measurements. Normetanephrine is particularly important in cardiac paraganglioma; 3-methoxytyramine may provide additional information in dopaminergic phenotypes or selected contexts. A normal result reduces the likelihood of a secreting mass, but leaves open the possibility of a biochemically silent lesion.
Preanalytical quality is part of interpretation. For plasma sampling, rest, appropriate posture and matching reference intervals are important; sampling after approximately 30 minutes supine reduces sympathetic activation compared with nonstandard conditions. Acute stress, severe illness and medications can cause elevations unrelated to a tumor. For urine testing, completeness of collection is checked, including by urinary creatinine. Any medication changes are agreed with the treating clinician, avoiding indiscriminate discontinuation to prepare for testing.
A marked elevation consistent with the clinical picture differs from a borderline-positive result. In the latter situation, sampling conditions, interference and pretest probability are reviewed, with proper repeat testing when necessary. A clonidine test may be used by specialists in selected cases of elevated normetanephrine, after verifying indications and safety. Chromogranin A and other nonspecific markers do not replace this assessment because they may rise due to conditions or treatments unrelated to paraganglioma.
Echocardiography describes location, relationships with chambers and valves, hemodynamic consequences and ventricular function. It can identify a paracardiac mass, but some posterior or great-vessel-adjacent sites are incompletely visualized. Transesophageal imaging provides further information in selected cases and during surgery. Vascular characterization and delineation of extent often require CT and MRI, even when echocardiography has already identified the lesion.
Contrast-enhanced cardiac CT often reveals an intensely enhancing mass and can trace feeding vessels, relationships with the aorta and pulmonary artery, continuity with the atria and interaction with the coronary arteries. Coronary CT angiography or invasive angiography, when indicated, contributes to vascular planning. The question is not simply which branch supplies the tumor, but which myocardial territories might be damaged if that branch were interrupted and which structures might require reconstruction.
On magnetic resonance imaging, T2 signal may be high, and post-contrast sequences demonstrate the rich perfusion. Flow voids related to high-flow vessels, hemorrhagic areas and different tissue components may produce heterogeneity. The classic appearance described for some paragangliomas in other anatomical regions is not mandatory in the heart. MRI primarily defines extent, relationships with the myocardium and cardiac function, complementing CT vascular findings and biochemical information.
The differential diagnosis includes cardiac hemangioma, other hypervascular masses, metastases, non-neoplastic vascular lesions and adjacent mediastinal tumors. A mass in a characteristic location associated with normetanephrine production makes the suspicion particularly strong. A negative biochemical result instead calls for closer integration with imaging and genetics. Intense contrast enhancement alone does not distinguish paraganglioma from every alternative.
Biopsy of the cardiac mass is not a routine step. Risks include hemorrhage and, in functional forms, catecholamine release with potentially serious instability. When biochemical and imaging findings are concordant, the diagnosis may be sufficiently robust to plan treatment without preliminary tissue sampling. If uncertainty remains that would radically change treatment, the case is discussed at an expert center, considering preparation, the safest sampling site and the actual usefulness of the specimen. Full histological characterization is often obtained during resection.
Functional imaging assesses disease distribution beyond the cardiac region and may inform treatment options. PET/CT with somatostatin-receptor tracers, such as gallium-68 DOTATATE, has a particularly important role in SDHx-associated forms. It can identify other primary sites and metastatic deposits, complementing an anatomical search that covers relevant regions. Tracer-avid findings must be correlated with morphology and context, because uptake alone does not automatically establish metastasis.
Other tracers, such as FDOPA and FDG, are selected according to phenotype, genotype, availability and the clinical question. FDG may be particularly informative in some biologically aggressive or SDHB-associated diseases, whereas choosing the most suitable tracer requires specialist expertise. MIBG scintigraphy remains relevant in selected settings, including assessment of possible eligibility for iodine-131 MIBG radionuclide therapy. A negative result on a single functional study does not exclude all forms of PPGL.
Genetic counseling is offered as part of the care pathway for patients with paraganglioma, with particular attention to cardiac location and the frequency of documented predispositions. An appropriate panel can identify variants that modify surveillance and make cascade testing of relatives relevant. The international consensus for asymptomatic carriers of SDHx variants defines a pathway distinct from that for patients already affected: genetic risk requires coordinated clinical, biochemical and imaging assessments, not simply repeat echocardiograms.
Preoperative assessment ultimately integrates resectability, endocrine activity, cardiac function and general condition. Relationships with the coronary arteries and great vessels, possible atrial or ventricular involvement, other lesions and reconstruction requirements are documented. A paraganglioma can be locally complex without metastases, or present as a relatively limited cardiac mass within multifocal disease. These situations call for different strategies and multidisciplinary discussion involving endocrinologists, cardiologists, cardiac surgeons, anesthesiologists, geneticists, nuclear medicine specialists and oncologists, as needed.
In secreting forms, alpha-adrenergic blockade precedes surgery and planned potentially hazardous manipulation. Doxazosin and phenoxybenzamine are options used according to availability and experience; the dose is titrated based on blood pressure, symptoms and orthostatic tolerance. Preparation generally takes days, often one or two weeks, although the actual duration depends on response and urgency. Even a normotensive patient with documented secretion may develop intraoperative instability and requires specific endocrine and anesthetic assessment.
A beta-blocker may be added to control tachycardia or arrhythmias after adequate alpha blockade. The sequence is essential: isolated beta blockade in the presence of unprepared catecholamine excess may allow alpha-mediated vasoconstriction to predominate and precipitate hemodynamic deterioration. Calcium-channel blockers and, in selected cases, metyrosine can support control; the latter reduces catecholamine synthesis and is used in specialist settings involving high secretion or difficulties with preparation.
Correction of volume depletion accompanies adrenergic control when appropriate. Fluid and sodium intake must, however, be tailored to ventricular function, congestion and renal function: a cardiac mass accompanied by cardiomyopathy may make indiscriminate volume expansion dangerous. Blood pressure in different positions, heart rate, weight and signs of fluid overload are monitored. Effective preparation seeks a balance among perfusion, crisis prevention and patient tolerance, rather than a single numerical target applied to every condition.
During anesthesia and surgery, hemodynamic monitoring appropriate to the complexity is necessary, with rapidly titratable medications available. Induction, manipulation and interruption of tumor vessels may cause marked fluctuations; after removal, the abrupt decrease in catecholamine stimulation can produce hypotension, compounded by vasodilation, residual medications and myocardial dysfunction. Postoperative monitoring also includes blood glucose, rhythm and perfusion, because hypoglycemia and other metabolic changes can occur.
Resection offers the principal opportunity for definitive control of localized disease when feasible at an acceptable risk. The approach depends on location: lesions adherent to the great-vessel roots, atria or coronary arteries may require cardiopulmonary bypass and complex reconstruction. Coronary blood supply must be controlled while preserving myocardial perfusion; some anatomical configurations require revascularization procedures. Endocrine preparation remains indispensable for functional forms even when the surgical issue appears primarily vascular.
Resections involving cardiac autotransplantation, allowing exposure of otherwise difficult-to-access regions, have been described in experienced centers, but these strategies are highly selective. Their availability may alter an initial assessment of inoperability without making extreme surgery appropriate for every patient. Possible preoperative embolization of feeding vessels requires particular caution because of the risk of coronary ischemia and hormone release; abundant vascularization alone is not a sufficient indication.
When disease is unresectable or metastatic, the plan distinguishes symptom control, reduction of secretion and antitumor treatment. Some slow-growing forms can be monitored, provided endocrine activity and local risk are managed; progression, a threatened organ or uncontrollable symptoms necessitate intervention. Debulking surgery, external-beam radiotherapy or local treatments may have selected indications. Irradiation of a cardiac site requires particularly careful planning to limit toxicity to the heart and surrounding tissues.
Radionuclide therapies are considered according to the lesions' ability to accumulate the tracer. Iodine-131 MIBG is relevant for disease showing adequate MIBG uptake; receptor-targeted therapy with lutetium-177 DOTATATE requires sufficient somatostatin-receptor expression. Selection integrates disease distribution, progression, bone marrow reserve and kidney function. Systemic treatment can also change hormone secretion, so adrenergic control and endocrinological care remain part of the pathway.
Systemic therapy may include cytotoxic regimens such as cyclophosphamide, vincristine and dacarbazine, temozolomide in selected patients, and agents targeting growth or angiogenic pathways. Selection depends on the rate of progression, genotype, previous treatments and comorbidities; evidence comes mainly from advanced PPGL considered as a whole, with very little cardiac-specific information. Antiangiogenic drugs may cause cardiovascular toxicity and require particular caution in patients with pre-existing cardiomyopathy or blood-pressure instability.
Among more recent options, belzutifan inhibits HIF-2α, targeting a pathway consistent with pseudohypoxia biology. The LITESPARK-015 trial, published by Jimenez and colleagues in 2025, demonstrated activity in advanced PPGL; its results concern a selected population and do not establish specific efficacy for every cardiac paraganglioma. In the United States, its indication for locally advanced, unresectable or metastatic PPGL was approved in 2025 for adults and patients aged 12 years and older. Actual use follows the authorized indications in the treatment setting and requires tolerability monitoring, including anemia, fatigue and respiratory disorders.
Prognosis depends on extent, the possibility of local control, catecholamine activity, genotype and pre-existing cardiovascular injury. A localized mass that is completely removed may follow a favorable course, with normalization of blood pressure or recovery of function. By contrast, metastatic disease behaves heterogeneously, from relatively slow evolution to faster progression. Tumor size alone or a low proliferative index does not allow a definitive individual prediction.
After resection of a functional tumor, biochemical testing assesses the decrease or normalization of metabolites after postoperative recovery. Persistent elevation requires consideration of residual disease, other secreting sites and factors interfering with the test. In initially silent forms, anatomical surveillance has greater importance because normal biochemistry alone cannot demonstrate the absence of disease. Ventricular function, valves, any reconstructed coronary arteries and rhythm are also reassessed.
Surveillance following PPGL surgery generally includes annual clinical and biochemical assessment, with imaging tailored to risk and secretory phenotype. European recommendations call for at least ten years of follow-up after resection and lifelong surveillance in high-risk patients, including carriers of genetic predisposition and patients with paraganglioma. For cardiac location, oncological and endocrine surveillance must be integrated with cardiological follow-up, especially after reconstruction or previous cardiomyopathy.
The care pathway for relatives depends on identifying a pathogenic variant and on the gene involved. Cascade testing enables surveillance to focus on carriers, using age-appropriate methods and schedules. A new paraganglionic mass or biochemical recurrence may appear many years later; therefore, transfers between centers and stages of life must preserve genetic and histological reports, imaging and the initial secretory profile. Resolution of symptoms is an important outcome, but disease control also requires this continuity of documentation.
Endocrine complications include hypertensive crises, cerebrovascular injury, myocardial ischemia, severe arrhythmias and cardiomyopathy, potentially progressing to shock and multiorgan failure. Local effects include coronary compression, valvular abnormalities, chamber obstruction and pericardial involvement. Metastatic progression may damage other organs and maintain or increase secretion. The risk of an acute event may exist even before anatomical growth becomes evident.
Perioperative complications include bleeding, vascular or myocardial injury, catecholamine crisis during manipulation and hypotension after removal. Biopsies and procedures performed without recognizing functional activity can precipitate instability; even a silent lesion retains a hemorrhagic risk because of its vascularization. After complex operations, ischemia, ventricular dysfunction, arrhythmias and the consequences of reconstruction must be considered. Endocrine preparation and anatomical planning address different risks and are both necessary for safe treatment.
Informational notice: the information contained on this page is provided solely for informational and educational purposes and does not replace the advice, diagnosis or treatment provided by a physician. If needed, always consult a qualified healthcare professional.
Artificial intelligence transparency: this page was created with the support of artificial intelligence tools, used to assist in the production and processing of its content.